Skip to main content
Log in

Phase I trial of tallysomycin S10b, a bleomycin analogue

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Bleomycin is an agent with significant antitumor efficacy whose major dose limiting toxicity is pulmonary fibrosis. Attempts have thus been made to identify congeners with reduced toxicity and with comparable or greater antitumor activity. Tallysomycin S10b is a bleomycin analogue possessing significantly greater potency, equal or reduced lung toxicity, and slightly greater antineoplastic activity when compared to the parent compound in preclinical studies. This report describes our experience with tallysomycin S10b in 30 patients with a variety of non-hematologic neoplasms. Pulmonary toxicity, occurring in 4 patients, was the major toxicity. The recommended cumulative dose of tallysomycin S10b was difficult to establish from the results of this study, as pulmonary toxicity appeared to be more idiosyncratic than dose-or schedule-dependent. The employment of more sensitive methods for detecting pulmonary toxicity in this study suggest that tallysomycin S10b may have reduced pulmonary toxicity compared to the parent compound.

Both bleomycin and tallysomycin S10b have similar t1/2 βhalf-lives of 2–4 h. Six patients had prolonged terminal elimination half-lives of tallysomycin S10b, but no clear relationship between this phenomenon and efficacy or toxicity was evident.

No complete or partial responses occurred. Disease stabilization occurred in 4 of 15 patients with diagnoses of renal cell carcinoma [2], rectal cancer [1] and lung cancer [1]. Five of eight patients with non-measurable disease had stable disease, including one with mesothelioma, one with carcinoma of the head and neck, two with renal cell cancer and one with colon carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Umezawa H, Meada K, Takeuchi I, Toshioka O: New antibiotics bleomycin A and B. J Antibiot A (Tokyo)19:200–206, 1966

    Google Scholar 

  2. Rodriguez V, Cabanillas F, Burgess MA, McKelvey E, Valdivieso M, Bodey G, Freireich EJ: Combination chemotherapy (“CHOP-bleo”) in advanced non-Hodgkin's malignant lymphoma. Blood49:325–333, 1977

    Google Scholar 

  3. Schein PS, DeVita VT, Hubbard S, Chabner BA, Canellos GP, Berard C, Young RC: Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Int Med 85:417–422, 1976

    Google Scholar 

  4. Krikorian JG, Portlock CS, Rosenberg SA: Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer 41:2107–2111, 1978

    Google Scholar 

  5. Kilmo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Int Med 102:596–602, 1985

    Google Scholar 

  6. Anderson KC, Skarin AT, Rosenthal DS, McIntyre JM, Pinkus GS, Case DC, Leonard RCF, Canellos GP: Combination chemotherapy for advanced non-hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. Cancer Treat Rep 68:1343–1350, 1984

    Google Scholar 

  7. Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Int Med 96:139–143, 1982

    Google Scholar 

  8. Bleier K: Relations between histology, TNM-category and results of treatment with methotrexate-bleomycin combination in squamous cell carcinoma of the oral cavity. J Maxillofac Surg 1:113–117, 1973

    Google Scholar 

  9. Einhorn LH, Donohue J: Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Int Med 87:293–298, 1977

    Google Scholar 

  10. Ginsberg SJ, Comis RL: The pulmonary toxicity of antineoplastic agents. Semin Oncol 9:34–51, 1982

    Google Scholar 

  11. Crooke ST, Einhorn LH, Comis RL, D'Aoust JC, Prestayko AW: The effects of prior exposure to bleomycin on the incidence of pulmonary toxicities. Med Pediatr Oncol 5:93–98, 1978

    Google Scholar 

  12. Samuels ML, Johnson DE, Holoye PY, Lanzotti VJ: Large dose bleomycin pulmonary toxicity. A possible role of prior radiotherapy. JAMA 235:1117–1120, 1976

    Google Scholar 

  13. Einhorn LH, Krause M, Hornback N, Furnas B: Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer 37:2414–2426, 1976

    Google Scholar 

  14. Skarin A, Lokich J, Goodman R: Combined intensive chemotherapy and radiotherapy in oat cell carcinoma of the lung. Proc Amer Soc Clin Oncol 16:264, 1975

    Google Scholar 

  15. Goldiner PL, Carlon GC, Cvitkovic E, Schweize O, Howland WS: Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1:1664–1677, 1978

    Google Scholar 

  16. Blum RH, Carter SK, Agre K: A clinical review of bleomycin. A new antineoplstic agent. Cancer 31:903–914, 1973

    Google Scholar 

  17. Hoogstraten B, Hass CD, Haut A, Talley RW, Rivkin S, Isaacs BL: CCNU and bleomycin in the treatment of cancer. A Southwest Oncology Group study. Med Pedatr Oncol 1:95–106, 1975

    Google Scholar 

  18. Miyaki T, Numata K, Nishiyama Y, Tenmyo O, Hatari M, Imanishi H, Konishi M, Kawaguchi H: Tallysomycin, a new antitumor antibiotic complex related to bleomycin. V. Production, characterization and antitumor activity to Tallysomycin S10b, a new biosynthetic tallysomycin derivative. J Antibiot (Tokyo) 34:665, 1981

    Google Scholar 

  19. Imanishi H, Ohbayashi M, Nishiyama Y, Kawaguchi H: Tallysomycin, a new antitumor antibiotic complex related to bleomycin. III. Antitumor activity of tallysomycins A and B. J Antibiot (Tokyo) 31:667–673, 1978

    Google Scholar 

  20. Schurig JE, Rose WC, Hirth RS, Schlein A, Huftalen JB, FLorczyk AP, Bradner WT: Tallysomycin S10b: Experimental antitumor activity and toxicity. Cancer Chemother Pharmacol 13:164–170, 1984

    Google Scholar 

  21. DeVita Vt, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology 2nd Ed. Philadelphia. Lippincott; 1982, p. 536.

    Google Scholar 

  22. Gaver RC, Dixon CW, Smyth RD: A radioimmunoassay procedure for tallysomycin S10b in human plasma and urine. Cancer Chemother Pharmacol 16(3):207–210, 1986

    Google Scholar 

  23. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed. Marcel Dekker, Inc. New York. 1982

    Google Scholar 

  24. Riegelman S, Collier P: The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokin Biopharm 8:509–534, 1980

    Google Scholar 

  25. Snedecor GW, Cochran WG: Statistical Methods. 7th Ed. Iowa State University Press. Ames Iowa, 1980, pp 149–174

    Google Scholar 

  26. Miller AB, Hoogstraten B, Staguet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    CAS  PubMed  Google Scholar 

  27. DeLena M, Guzzon A, Monfardini S, Bonnadonna G: Clinical, radiological and histopathological studies on pulmonary toxicity induced by treatment with bleomycin (NSC 125066). Cancer Chemother Rep 56:343–356, 1972

    Google Scholar 

  28. Alberts DS, Chen H, Liu R, Himmelstein KJ, Mayerson M, Perrier D, Gross J, Moon T, Broughton A, Salmon SE: Bleomycin pharmacokinetics in man. I. Intravenous administration. Cancer Chemother Pharmacol 1:177–181, 1978

    Google Scholar 

  29. Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS: Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 9:22–25, 1982

    Google Scholar 

  30. Crooke ST, Comis RL, Einhorn L, Strong JE, Broughton A, Prestayko AW: Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an IV Bolus. Cancer Treat Rep 61(9):1631–1636, 1977

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paolozzi, F.P., Gaver, R.C., Newman, N.B. et al. Phase I trial of tallysomycin S10b, a bleomycin analogue. Invest New Drugs 8, 171–180 (1990). https://doi.org/10.1007/BF00177253

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00177253

Key words

Navigation